|
The Histiocytosis Program at Children’s Hospital and Vanderbilt University Medical Center offers comprehensive diagnostic, consultative and therapeutic services for children and adults with Langerhans cell histiocytosis (LCH; also known as eosinophilic granuloma or histiocytosis X), hemophagocytic lymphohistiocytosis (HLH), Rosai-Dorfman disease (RDD; also known as sinus histiocytosis with massive lymphadenopathy), juvenile xanthogranuloma (JXG), and other less common histiocytic disorders.
 Histiocytosis is a rare blood disease that affects 1 in 200,000 children born each year in the United States. It is caused by an excess of white blood cells called histiocytes. The histiocytes cluster together and can attack the skin, bones, lung, liver, spleen, gums, ears, eyes, and/or the central nervous system. The disease can range from limited involvement that spontaneously goes into remission without treatment to progressive multi-organ involvement that can be chronic and debilitating. In some cases, the disease can be life-threatening.
In some ways, histiocytosis is similar to cancer and has historically been treated by oncologists with chemotherapy and radiation. The vast majority of people diagnosed with histiocytosis are children under the age of 10, but it is also found in adults of all ages.
- Consultations for patients with newly diagnosed or recurrent histiocytosis
- Individualized treatment plans for patients with newly diagnosed or recurrent histiocytosis
The Vanderbilt Histiocytosis program participates in international clinical trials conducted by the Histiocyte Society. Please contact us at 615.936.1762 for more information about open clinical trials here at Vanderbilt.
For more information about the various forms of histiocytosis, please visit the website of the Histiocytosis Association of America.
To make an appointment or request more information, please call us at 615.936.1762.
|
